Matinas BioPharma Holdings (MTNB) has disclosed a new risk, in the Innovation / R&D category.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Matinas BioPharma Holdings faces significant business risk following the discontinuation of its lead product candidate, MAT2203, due to the termination of negotiations for global rights. The company has reduced its workforce by 80% and halted all product development activities to conserve cash, while seeking strategic alternatives that may not materialize. The uncertainty surrounding the potential for a successful transaction, including the possibility of dissolution, poses a threat to shareholder value and future research endeavors. Additionally, any strategic transaction undertaken may lead to increased expenditures and integration challenges, further complicating the company’s operational stability.
Overall, Wall Street has a Hold consensus rating on MTNB stock based on 2 Holds.
To learn more about Matinas BioPharma Holdings’ risk factors, click here.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue